---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-097535"
form_type: "8-K"
ticker: "BOLD"
cik: "0001782303"
company_name: "Boundless Bio, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:04:43.981776+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Boundless Bio Q4 net loss $12.9M; cash $107.6M; ceases POTENTIATE enrollment; BBI-940 trial enrolling

## Summary
- Net loss of $12.9M for Q4 2025 and $58.2M for FY2025, vs $16.4M and $65.4M in same periods of 2024.
- Cash, cash equivalents, and short-term investments total $107.6M; expected runway into H2 2028 through initial proof-of-concept readout for KOMODO-1.
- Ceased enrollment in Phase 1/2 POTENTIATE trial (BBI-355 + BBI-825) due to market considerations and prioritization of BBI-940 program.
- KOMODO-1 first-in-human trial of BBI-940 (oral Kinesin degrader) open for enrollment in ER+/HER2- and TNBC-LAR breast cancer.
- Director Christine Brennan resigned effective March 3, 2026 due to new role at Johnson & Johnson Development Corp., no disagreement.

## SEC filing metadata
- accession: 0001193125-26-097535
- form_type: 8-K
- ticker: BOLD
- cik: 0001782303
- company_name: Boundless Bio, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097535/0001193125-26-097535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782303/000119312526097535/bold-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-097535
- JSON: https://secwatch.observer/filing/0001193125-26-097535.json
- Plain text: https://secwatch.observer/filing/0001193125-26-097535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.